10:30 a.m. New York time
My options positions, which will reach Management Day on Friday, have improved considerably since yesterday’s market-wide decline. Out of eight positions expiring in February, four are profitable and, if that continues, will be sold on Friday. Four are unprofitable, and I’ll hang on to each of them until it becomes profitable or we’re close to expiration. Only one of the four, XLE, is beyond its profit zone. The underlying is trading for $55.53 at present, and the put strike is at $56.21.
The positions, all of them short iron condors, are on EEM, TLT, XBI, XLE, XLI, XLK, XLV and XLY.
In stocks, today’s focus is on the Genetics Portfolio. There were no exits. I opened five new positions in several portfolios, taking care to ensure that each was in an uptrend as well as meeting my other criteria. In terms of portfolios, the new positions are all over the map.
- Genetics Portfolio
- AAPL, for a $313.86 debit per share.
- EDIT, a $28.99 debit.
- Robotics Portfolio
- ADSK, a $196.38 debit.
- KBH, a $38.66 debit.
- JCAP, a real estate investment trust with a buy score from Zacks and a 7% dividend, for a $20.02 debit.
By Tim Bovee, Portland, Oregon, January 28, 2020
Tim Bovee, Private Trader tracks the analysis and trades of a private trader for his own accounts. Nothing in this blog constitutes a recommendation to buy or sell stocks, options or any other financial instrument. The only purpose of this blog is to provide education and entertainment.
No trader is ever 100 percent successful in his or her trades. Trading in the stock and option markets is risky and uncertain. Each trader must make trading decisions for his or her own account, and take responsibility for the consequences.
All content on Tim Bovee, Private Trader by Timothy K. Bovee is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Based on a work at www.timbovee.com.